New vaccine aims to keep deadly parasite at bay in african kids
NCT ID NCT00870649
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tested a vaccine called Bilhvax, given alongside a standard treatment (praziquantel), to see if it could delay the return of schistosomiasis in children. About 250 infected children aged 6 to 9 in Senegal received three vaccine shots plus a booster, or a placebo. The goal was to reduce the risk of the disease coming back over three years, while also checking for safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHISTOSOMA HAEMATOBIUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ESPOIR Pour La Santé
Saint-Louis, Senegal
Conditions
Explore the condition pages connected to this study.